Cytek Biosciences Inc. (CTKB)’s liquidity ratios and what they mean


The price of Cytek Biosciences Inc. (NASDAQ: CTKB) closed at $6.69 in the last session, down -4.43% from day before closing price of $7.00. In other words, the price has decreased by -$0.31 from its previous closing price. On the day, 543240 shares were traded. CTKB stock price reached its highest trading level at $6.98 during the session, while it also had its lowest trading level at $6.69.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.



We take a closer look at CTKB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.70 and its Current Ratio is at 7.90. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 07 when Jiang Wenbin sold 20,000 shares for $6.83 per share. The transaction valued at 136,600 led to the insider holds 7,605,796 shares of the business.

Jeanmonod Patrik sold 3,000 shares of CTKB for $23,070 on Aug 24. The Chief Financial Officer now owns 102,084 shares after completing the transaction at $7.69 per share. On Aug 21, another insider, Yan Ming, who serves as the Chief Technology Officer of the company, sold 20,000 shares for $8.07 each. As a result, the insider received 161,400 and left with 7,815,962 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 912.25M and an Enterprise Value of 629.62M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.24 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 3.59 whereas that against EBITDA is -1.69k.

Stock Price History:

Over the past 52 weeks, CTKB has reached a high of $15.90, while it has fallen to a 52-week low of $6.45. The 50-Day Moving Average of the stock is 8.32, while the 200-Day Moving Average is calculated to be 9.59.

Shares Statistics:

According to the various share statistics, CTKB traded on average about 877.03K shares per day over the past 3-months and 1.42M shares per day over the past 10 days. A total of 135.92M shares are outstanding, with a floating share count of 120.69M. Insiders hold about 11.80% of the company’s shares, while institutions hold 53.10% stake in the company. Shares short for CTKB as of Aug 30, 2023 were 11.82M with a Short Ratio of 11.82M, compared to 12.02M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.67% and a Short% of Float of 9.80%.

Earnings Estimates

The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.02 for the current quarter, with a high estimate of $0.04 and a low estimate of $0.01, while EPS last year was $0.04. The consensus estimate for the next quarter is $0.06, with high estimates of $0.08 and low estimates of $0.04.

Analysts are recommending an EPS of between $0.21 and $0.06 for the fiscal current year, implying an average EPS of $0.12. EPS for the following year is $0.22, with 4 analysts recommending between $0.25 and $0.2.

Revenue Estimates

According to 4 analysts, the current quarter’s revenue is expected to be $57.64M. It ranges from a high estimate of $61.7M to a low estimate of $53.17M. As of the current estimate, Cytek Biosciences Inc.’s year-ago sales were $43.29M, an estimated increase of 33.10% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $65.22M, an increase of 34.90% over than the figure of $33.10% in the same quarter last year. There is a high estimate of $68.2M for the next quarter, whereas the lowest estimate is $60.44M.

A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $214M, while the lowest revenue estimate was $200.4M, resulting in an average revenue estimate of $209.66M. In the same quarter a year ago, actual revenue was $164.04M, up 27.80% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $276.3M in the next fiscal year. The high estimate is $289.2M and the low estimate is $252.29M. The average revenue growth estimate for next year is up 31.80% from the average revenue estimate for this year.


Please enter your comment!
Please enter your name here